The present study was undertaken to acquire a rationale for clinical dose adjustment of anti-thymocyte globulin (ATG) to improve cost effectiveness and safety of graft-versus-host disease prophylaxis. The concentration of rabbit ATG in the serum of 12 patients was measured by ELISA and by the inhibitory effect on phytohaemagglutinin-induced blastogenesis. At 10 mg/ml ATG, 3 H-thymidine incorporation was effectively blocked. Serial two-fold dilution of ATG showed that this effect decreased in a concentration-dependent manner and was lost at 10 ng/ml ATG. One hundred microlitres serum taken at day ؊1 to ؉22 post transplant effected significant inhibition of the phytohaemagglutinin-response with 49 ؎ 12% c.p.m. (x ؎ s.d.) on day ؉1 post transplant compared to 93 ؎ 13% c.p.m. on day ؊1 (P Ͻ 0.001, unpaired one-sided t-test). The rabbit-IgG was maximal at a concentration of 907 ؎ 187 l/ml at day 0. Subsequently, it decreased with time. While rabbit-IgG was detectable for a long period (eg 160 g/ml at day ؉22 in patient MD), the effect on the phytohaemagglutinin-response of normal mononuclear cells lasted up to 4 days post transplant. We conclude that 90 mg/kg body weight ATG-Fresenius given prior to marrow transplant leads to sustained T cell immunosuppression post transplant. Keywords: graft-versus-host disease; immunotherapy; T lymphocytes; transplantation Anti-thymocyte globulin (ATG) preparations have been used successfully in transplantation, aplastic anaemia and graft-versus-host disease (GVHD).
Anti-thymocyte globulin (ATG) preparations have been used successfully in transplantation, aplastic anaemia and graft-versus-host disease (GVHD).
1-3 ATG-Fresenius is a polyclonal serum raised in rabbits against the Jurkat T cell line. 4 As indicated by previous reports, standardisation of in vitro and clinical activity of polyclonal ATG is a complex issue. [5] [6] [7] [8] The present study was undertaken to acquire a rationale for clinical dose adjustment to improve cost effectiveness and safety of GVHD prophylaxis. Rabbit ATG concentration was measured in the serum by ELISA and by inhibition of phytohaemagglutinin-induced blastogenesis.
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Patients and methods

Clinical protocol
Twelve patients (nine chronic myelogenous leukaemia, one acute myeloid leukaemia, one acute lymphoblastic leukaemia, one plasmacytoma) were studied, average age 41 (range 21-55 years). The average body weight was 79 Ϯ 16 kg (x Ϯ s.d.; range 52-106). Six patients had received marrow from a matched unrelated donor and six from an HLA-identical sibling. Conditioning therapy consisted of 1200 cGy total body irradiation and 60 mg of cyclophosphamide per kg of body weight per day for 2 days, or busulphan, cyclophosphamide and etoposide. ATG-Fresenius (30 mg/kg) was administered intravenously to 12 subsequent patients daily in three doses on days −3 to −1. Additional GVHD prophylaxis consisted of cyclosporine, methothrexate, mitromidazole and pentaglobulin, an IgM-enriched immunoglobulin preparation. 9 
Mitogen assay
Peripheral blood mononuclear cells (PBMC) from healthy volunteers were isolated from 20 ml heparinized human peripheral blood by centrifugation on Ficoll-Hypaque (Lymphoflot; Biotest, Dreieich, Germany) using standard methods. Quadruplicate cultures of 1 × 10 5 PBMC were plated in 96-well round-bottom microtitre plates (Greiner 650180, Frickenhausen, Germany) in 100 l RPMI 1640 supplemented with 10% fetal calf serum (FCS; Biochrom, Berlin, Germany) and 100 U/ml penicillin/streptomycin (GibcoBRL, Life Technologies, Eggenstein, Germany). Sera of patients (100 l) treated with rabbit ATG (Fresenius, Bad Homburg, Germany) at various time points before or after bone marrow transplantation, serial dilution of ATG (range 10 mg/ml-2.4 g/ml), or media control were added. The cells were stimulated for 48 h at 37°C with 5 g/ml phytohaemagglutinin (PHA-L; Boehringer Mannheim, Mannheim, Germany). The proliferative response was measured by adding 1 Ci 
Data analysis and statistical procedures
PHA-response was calculated as the mean of quadruplicates and given as a percentage of the maximal response obtained in the absence of ATG (% c.p.m.). An unpaired one-sided t-test was used to determine the significance (P value) of differences at various time points.
Results
Anti-thymocyte globulin was tested for its ability to inhibit the blastogenic response of normal mononuclear cells to the mitogen PHA. A dose-response decrease of the c.p.m. could be demonstrated (Figure 1 ). At 10 mg/ml ATG, 3 Hthymidine incorporation was effectively blocked. Serial two-fold dilution of ATG showed that this effect decreased over a wide range and was lost at an ATG concentration of 10 ng/ml. A relationship between the amount of ATG and the decrease of c.p.m. could therefore be established. Figure 2 shows the mean effect of 100 l serum taken at day −1 to +22 post transplant from the 12 subjects on the PHA response of normal PBMC. Significant inhibition of the PHA-response (bars) was observed on day 0 (58 Ϯ 32% c.p.m.) and day +1 post transplant (49 Ϯ 12% c.p.m., P Ͻ 0.001).
The concentration of rabbit-IgG in the serum (curve), mean Ϯ standard deviation showed a maximum of 907 Ϯ 187 l/ml (x Ϯ s.d.) at day 0. Thereafter, rabbit-IgG decreased steadily. Individual samples taken between days +6 to +22 were grouped (Ͼ5). The rabbit-IgG concentration was at 270 Ϯ 129 l/ml. Rabbit-IgG was detectable for a long period; for example, in patient MD, 160 g/ml rabbitIgG was observed at day +22 post-BMT, although an effect on the PHA-response of normal PBMC was not observed in any case after day +4 post transplant.
Discussion
We report the persistence of rabbit-IgG in vivo for up to 3 weeks after ATG administration. In order to permit functional quantification of ATG in lymphocyte-depleted recipients of bone marrow grafts, ex vivo inhibition on PHAinduced blastogenesis of normal mononuclear cells was used. This method showed a good dose-response inhibition over 6 logs ATG concentrations (Figure 1) .
In Figure 2 , we present the correlation between the rabbit-IgG concentration in the serum and the relative inhibition (% c.p.m.) of PHA-response of mononuclear cells in 12 patients. On days 1 and 2 after ATG administration had been stopped, the concentration of ATG was still T cell inhibitory. Thereafter, this effect disappeared, while rabbitIgG was still detectable.
A long mean elimination half-life of 29 days (range 14-45) of rabbit-IgG was reported by Bunn et al. 10 Differences in the elimination of individual anti-thymocyte antibody specificities were seen in a rhesus monkey kidney allograft model by immunoprecipitation of 125 I-labeled monkey PBMC lysates. 11 Following 50 mg/kg rabbit-ATG on days 0-4 after transplant, antibodies against CD8, MHC class I and CD28 persisted until day +15, while antibodies against CD4 and CD16 disappeared before day +13. Our data are in agreement with these observations. A functional level of T cell inhibitory antibody specificities of rabbit ATG-Fresenius, which comprise mainly antibodies against CD2, CD5, CD7 and CD45, 8 was detectable on day 0 and +1 post BMT, persisting in some patients until day +4 (data not shown), but it was absent long before lymphocyte recovery in recipients took place. This begins at approximately day +14 post transplant. 12 For the given overall dose of ATG-Fresenius (90 mg/kg body weight) the result indicates that in vivo T cell immunosuppressive concentrations were attained even after the infusion of unmanipulated marrow. Thus, in vivo T cell depletion of the graft must have been accomplished at saturating concentrations of ATG-Fresenius. It remains to be ascertained whether a further dose reduction can be achieved without losing the impact on the graft-versus-host reaction.
Anti-thymocyte globulin was first used in bone marrow transplantation by Storb et al 13 to prevent rejection of second marrow grafts in patients with aplastic anemia. Later, it was recognized that this regimen not only prevented rejection but also resulted in a low incidence of GVHD. 14, 15 Based on this initial observation, ATG was included in the conditioning regimen in our transplantation protocol as prophylaxis for GVHD. 15 The outcome in matched unrelated donor transplantation is at the time of analysis 68% overall survival with moderate incidence of GVHD and no increase in relapse rate (Ref. 9, manuscript submitted).
Although ATG-Fresenius was ineffective in the treatment of aplastic anaemia 7 its clinical efficacy as prophylaxis for GVHD has been confirmed recently by others. 16, 17 ATG-Fresenius was chosen because with the Jurkat T cell line the immunizing antigen is standardized and readily available. This should facilitate the direct detection of antiJurkat antibodies in sera from treated patients. Jurkat cells resemble activated T cell blasts, which constitutively express IL-2 and the IL-2 receptor. Thus, Jurkat cells may be an appropiate immunogen to elicit antibodies against activated T cells for prevention of GVHD.
In conclusion, we show by ex vivo inhibition of T cell proliferation that ATG administration prior to BMT leads to an immunosuppression of PHA-responses post transplant, which might be a mechanism for prevention of GVHD.
